EVE Health launches Libbo in Australia with end-to-end digital platform
EVE Health Group (ASX: EVE) has commenced the commercial launch of Libbo, its oral dissolving film treatment for erectile dysfunction, marking a transition from manufacturing and distribution into active revenue generation. The EVE Health Libbo Launch includes the activation of an integrated digital ecosystem encompassing the stiffissue.com platform, telehealth prescribing through hubMed and TeleDocs Clinic, and pharmacy fulfilment via Chemist2U. This end-to-end infrastructure enables eligible patients to access assessment, consultation, prescription, and direct delivery through a streamlined digital pathway.
The announcement, released on 10 February 2026, represents EVE’s first commercial revenue opportunity from Libbo following the completion of manufacturing and delivery of inventory into national distribution. The vertically integrated model positions the company for scalable national access whilst addressing documented barriers to erectile dysfunction treatment, including stigma, privacy concerns, and inconvenience of traditional healthcare pathways.
The patient access pathway operates through four defined stages:
- Digital Assessment – Patients complete clinical evaluation through the stiffissue.com platform
- Telehealth Consultation – Referral to independent prescribers (hubMed or TeleDocs Clinic) for medical consultation
- Prescription Issuance – Where clinically appropriate, prescriptions are issued by registered medical practitioners
- Direct Delivery – Pharmacy fulfilment through Chemist2U enables discreet direct-to-patient delivery
This integrated approach establishes what the company describes as a regulated healthcare framework designed to support responsible prescribing, patient engagement, and national access within Australia’s authorised prescriber frameworks.
What is oral dissolving film technology and why it matters
Oral dissolving films are thin pharmaceutical strips placed on the tongue that dissolve rapidly without water. For erectile dysfunction treatment, this delivery method offers several potential advantages over traditional tablet formulations.
The format provides:
- Rapid onset – Dissolved medication enters the bloodstream faster through buccal absorption
- Enhanced convenience – No water required for administration
- Improved discretion – Compact format suitable for discreet use
- Potentially enhanced bioavailability – EVE’s proprietary formulation technology targets improved drug absorption
The differentiated product format may drive patient preference in a market where treatment uptake remains suboptimal despite the availability of effective therapies. EVE’s proprietary formulation and delivery technologies create competitive positioning in the oral dissolving film segment.
The Australian erectile dysfunction market opportunity
Erectile dysfunction affects approximately one in five adult men in Australia, with prevalence increasing to up to 40% of men over the age of 40. Despite the availability of effective therapies, the condition remains undertreated due to multiple access barriers.
Common treatment barriers documented in the announcement include stigma, privacy concerns, and inconvenience of traditional healthcare pathways. A key factor contributing to reduced engagement is limited understanding that erectile dysfunction is frequently linked to underlying health factors and is, in most cases, readily treatable with appropriate medical support.
The large addressable market combined with documented access gaps creates commercial opportunity for digital-first solutions that reduce psychological and practical barriers to treatment. Traditional healthcare pathways can present obstacles that contribute to suboptimal patient outcomes, positioning alternative access models as potentially complementary to existing treatment options.
EVE’s integrated commercial model explained
EVE is executing a vertically integrated commercial model that combines proprietary pharmaceutical products with digital engagement and clinical networks. This approach differs materially from traditional pharmaceutical distribution, where manufacturers typically supply products through wholesale channels with limited visibility into end-patient access.
The company’s integrated platform comprises three core components working in sequence:
| Platform Component | Partner/Asset | Function |
|---|---|---|
| Digital Gateway | stiffissue.com | Education, onboarding, clinical assessment |
| Telehealth Prescribing | hubMed, TeleDocs Clinic | Medical consultation and prescription |
| Pharmacy Fulfilment | Chemist2U | Direct-to-patient delivery |
Libbo is being commercialised through established telehealth prescribing pathways and pharmacy fulfilment partners, leveraging authorised prescriber frameworks and national distribution infrastructure already in place. The model is designed to accelerate market entry, support patient access, and build sustainable revenue streams in men’s health.
The digital platform serves dual purpose. It provides patient access infrastructure operational today whilst establishing foundation architecture for future product extensions and expansion into additional therapeutic indications. This infrastructure-first approach means platform economics may improve as additional products are introduced, with operational leverage increasing as the fixed cost base is amortised across multiple revenue streams.
Vertical integration may support higher margins and faster market penetration compared to traditional wholesale models where manufacturers capture only wholesale pricing. Direct engagement with end patients through the digital gateway also provides EVE with customer data and feedback loops that can inform product development and market positioning.
CEO commentary on the commercial milestone
Damian Wood, Chief Executive Officer
“The commencement of Libbo’s commercial launch represents a key milestone in EVE’s transition from manufacturing and distribution into real-world patient access. With the stiffissue.com digital platform now live and prescribing and fulfilment pathways operational, we have established the core infrastructure required to support scalable national access in men’s health. This milestone reflects the disciplined execution of our commercial strategy and positions the Company to build a meaningful and sustainable presence in the men’s health sector.”
The statement frames the launch as validation of EVE’s commercial strategy execution, emphasising the transition from supply readiness into active market participation. With operational infrastructure now established, the company is positioned to begin generating revenue from Libbo whilst building towards sustainable market presence in men’s health.
What comes next for EVE Health
The activated digital infrastructure creates foundation architecture that can be leveraged for future product extensions and additional therapeutic indications beyond erectile dysfunction. The company’s pipeline includes a second lead asset targeting a different patient population and therapeutic area.
EVE’s two lead commercial assets are:
- Libbo – Oral dissolving film for erectile dysfunction (now launched commercially in Australia)
- Dyspro – Fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis (in development)
The addition of Dyspro to the commercial pipeline would enable EVE to build presence across both men’s and women’s health, potentially creating operational leverage from the digital platform architecture and clinical networks established for Libbo. Platform economics improve as additional products are introduced, with fixed infrastructure costs distributed across multiple revenue streams.
Both products leverage EVE’s proprietary formulation and delivery technologies designed to enhance bioavailability and clinical outcomes. The company positions these assets as near-term commercial opportunities in what it describes as large, underserved global markets where patient access barriers create gaps between treatment availability and treatment uptake.
The commercial launch of Libbo establishes EVE’s first active revenue-generating asset whilst demonstrating proof of concept for its integrated digital-to-delivery model. Pipeline visibility with Dyspro in development for women’s health provides potential pathway for sustainable growth beyond the initial men’s health focus.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements the moment they break, with all the analysis already done.